Want to see HOWL full AI Analyst Report?
Total Valuation
Werewolf Therapeutics has a market cap or net worth of $18.39M. The enterprise value is $7.92M.
Market Cap$18.39M
Enterprise Value$7.92M
Share Statistics
Werewolf Therapeutics has 48,596,817 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,596,817
Owned by Insiders20.31%
Owned by Institutions21.79%
Financial Efficiency
Werewolf Therapeutics’s return on equity (ROE) is -2.45 and return on invested capital (ROIC) is -173.37%.
Return on Equity (ROE)-2.45
Return on Assets (ROA)-0.88
Return on Invested Capital (ROIC)-173.37%
Return on Capital Employed (ROCE)-1.82
Revenue Per Employee0.00
Profits Per Employee-1.32M
Employee Count46
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Werewolf Therapeutics is ―. Werewolf Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio1.18
Price to Fair Value1.18
Price to FCF-0.48
Price to Operating Cash Flow-0.38
PEG Ratio0.03
Income Statement
In the last 12 months, Werewolf Therapeutics had revenue of 0.00 and earned -60.82M in profits. Earnings per share was -1.32.
Revenue0.00
Gross Profit-1.63M
Operating Income-60.68M
Pretax Income-60.82M
Net Income-60.82M
EBITDA-53.91M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -51.94M and capital expenditures 0.00, giving a free cash flow of -51.94M billion.
Operating Cash Flow-51.94M
Free Cash Flow-51.94M
Free Cash Flow per Share-1.07
Dividends & Yields
Werewolf Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.05
52-Week Price Change-66.13%
50-Day Moving Average0.46
200-Day Moving Average0.86
Relative Strength Index (RSI)52.01
Average Volume (3m)1.22M
Important Dates
Werewolf Therapeutics upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Werewolf Therapeutics as a current ratio of 1.62, with Debt / Equity ratio of 308.56%
Current Ratio1.62
Quick Ratio1.62
Debt to Market Cap0.06
Net Debt to EBITDA0.90
Interest Coverage Ratio-11.50
Taxes
In the past 12 months, Werewolf Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Werewolf Therapeutics EV to EBITDA ratio is 0.36, with an EV/FCF ratio of 0.32.
EV to Sales0.00
EV to EBITDA0.36
EV to Free Cash Flow0.32
EV to Operating Cash Flow0.32
Balance Sheet
Werewolf Therapeutics has $46.45M in cash and marketable securities with $37.65M in debt, giving a net cash position of $8.80M billion.
Cash & Marketable Securities$46.45M
Total Debt$37.65M
Net Cash$8.80M
Net Cash Per Share$0.18
Tangible Book Value Per Share$0.54
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Werewolf Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast26.30%